



Press communication

Lund, Sweden, 13 October 2022

This is a translation of the Swedish press release published 2022-10-13

Neola Medical's new trademark has been registered in the European Union

Neola Medical AB (publ) announces today that the company's new trademark has been registered in the European Union. The new trademark is part of the company's name change that was implemented the 28th of June 2022. The registration in EU is important for the company's brand building.

"We are happy to have this trademark registered for Neola® and for the company's logotype in all countries within the European Union. It is an important asset in our portfolio at the same time as we secure the company's trademark even further before the commercial launch.", says Hanna Sjöström, CEO at Neola Medical.

In connection with the name change the 28th of June 2022 a new graphic profile was launched to match the company's position as a medicine technology company within neonatal intensive care. Furthermore, a new logotype was launched with accompanied symbol illustrating lungs at the same time as the letter N. The trademark registration of this new logotype is an important strategic asset, strengthening the company's positioning on the international market.

For further information, contact

Hanna Sjöström, CEO Neola Medical, tel: 0760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com

Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants' lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.